NCT06880276View on ClinicalTrials.gov

Efficacy and Safety Study of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis

PHASE3RecruitingINTERVENTIONAL
Enrollment

360

Participants

Timeline

Start Date

May 16, 2025

Primary Completion Date

March 31, 2027

Study Completion Date

May 31, 2027

Conditions
Atopic Dermatitis
Interventions
DRUG

1.5% QLM3003 ointment

QLM3003 topical cream; 1.5% cream applied twice daily (BID)

DRUG

2% QLM3003 ointment

QLM3003 topical cream; 2% cream applied twice daily (BID)

DRUG

QLM3003 Placebo

vehicle; vehicle applied twice daily (BID)

Trial Locations (1)

Unknown

RECRUITING

The First Affiliated Hospital of China Medical University, Shenyang

All Listed Sponsors
lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY